Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients

Abstract excerpt

Imatinib mesylate (IM) is highly efficacious in the treatment of Chronic Myeloid Leukemia (CML). Therapeutic drug monitoring and pharmacogenetic screening are warranted for better management of imatinib therapy. The goal of this study was to gain a greater mechanistic understanding of the factors governing variable imatinib level and its relationship to response. One hundred and two patients with CML at chronic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments
• Share to Eosinophilic Disorders and Syndromes